Nanovis completed a US $5.5MM funding round to support sales and distribution of its FortiCore® interbody fusion devices.
Investors in the round included Elevate Ventures, 1st Source Capital Corporation, Purdue’s Foundry Investment Fund, Commenda Capital and Ellipsis Ventures.
Nanovis received initial FDA 510(k) marketing clearance for FortiCore devices in 2014. The company gained an additional FDA 510(k) in 1Q18 for FortiCore® interbody fusion devices that feature a Nanosurface-enhanced porous titanium scaffold, intermolded with a PEEK core. These devices are intended for use in transforaminal and anterior lumbar interbody fusion procedures (TLIF and ALIF).
Nanovis completed a US $5.5MM funding round to support sales and distribution of its FortiCore® interbody fusion devices.
Investors in the round included Elevate Ventures, 1st Source Capital Corporation, Purdue’s Foundry Investment Fund, Commenda Capital and Ellipsis Ventures.
Nanovis received initial FDA 510(k) marketing clearance for...
Nanovis completed a US $5.5MM funding round to support sales and distribution of its FortiCore® interbody fusion devices.
Investors in the round included Elevate Ventures, 1st Source Capital Corporation, Purdue’s Foundry Investment Fund, Commenda Capital and Ellipsis Ventures.
Nanovis received initial FDA 510(k) marketing clearance for FortiCore devices in 2014. The company gained an additional FDA 510(k) in 1Q18 for FortiCore® interbody fusion devices that feature a Nanosurface-enhanced porous titanium scaffold, intermolded with a PEEK core. These devices are intended for use in transforaminal and anterior lumbar interbody fusion procedures (TLIF and ALIF).
Copy to clipboard 
